Skip to main content
Premium Trial:

Request an Annual Quote

People Transfer: Sep 2, 2009

Premium

BioForward, an organization representing Wisconsin's biotechnology industry, has appointed Bryan Renk as executive director, effective Oct. 1.

Renk joins BioForward from aOva Technologies, where he served as president and director. Previously he held positions as director of licensing at the Wisconsin Alumni Research Foundation and director at Wm F Renk and Sons.

Renk currently sits on the board of Maple Leaf Farms, FluGen, and the Wisconsin Agricultural and Life Sciences Alumni Association. He holds MS and BS degrees in meat and animal science and muscle biology from UW-Madison.


The BioInnovation Institute in Akron, Ohio, said recently that Frank Douglas has joined the institute as president and CEO.

Douglas is the former founder and executive director of the Massachusetts Institute of Technology's Center of Biomedical Innovation. He has also served as a senior fellow at the Ewing Marion Kauffman Foundation; senior partner at Puretech Ventures; and chief scientific advisor for Bayer Healthcare. Douglas has also been a faculty member at the Massachusetts Institute of Technology.

Douglas holds a PhD in physical chemistry and MD from Cornell University, and completed an internship and residency in internal medicine at the Johns Hopkins Medical Institution, as well as a fellowship in neuroendocrinology at the National Institutes of Health.


City of Hope has appointed Robert Stone to the newly created position of chief strategy and administrative officer.

Stone previously served as general counsel for City of Hope, which he joined in 1996 as associate general counsel. He was subsequently promoted to general counsel for the medical center in 2000. Prior to City of Hope, Stone served as an associate attorney at the law firms of Christa & Jackson and Hanna & Morton. He holds a law degree from the University of Chicago Law School.

City of Hope also said that Gregory Schetina will replace Stone as general counsel. Schetina previously served as chief deputy general counsel for the research institution. Previously, he was a partner with the law firms of Jones Day and Tuttle & Taylor. He holds a law degree from Loyola Law School.


David Dykeman, intellectual property and technology shareholder at Greenberg Traurig, has been appointed to the Massachusetts Life Sciences Collaborative's Research, Innovation, and Commercialization Task Force.

Dykeman is a registered patent attorney with more than 13 years of experience in patent and intellectual property law. He serves on the board of directors of the Massachusetts Medical Device Industry Council.

The MLSC task force was founded in the spring of 2006 with support from The Boston Foundation, the University of Massachusetts, Harvard University, the Massachusetts Institute of Technology, and the Massachusetts Technology Collaborative's John Adams Innovation Institute.

The task force includes CEOs, academics, and venture capitalists in the life sciences and provides strategic guidance on issues related to life sciences innovation in Massachusetts. Dykeman is the only patent attorney on the task force.


Life sciences venture capital firm Alta Partners has promoted Robert Alexander to the position of director.

Alexander currently represents Alta as a director on the boards of SARCode and Sonexa, two Alta Partners portfolio companies. He joined Alta as a principal in 2005. Prior to that, he was a principal with MPM Capital's BioEquities fund, which he joined after working in business development at Genentech.

Alexander completed his postdoc at Stanford University in the department of pathology. He holds a PhD in immunology from the University of North Carolina.

Alta also said that Adam Tomasi has been promoted to principal. Tomasi joined the company as a Kauffman Fellow in 2006. Prior to that, he was a student in the Harvard-MIT Biomedical Enterprise program and held lead scientific positions at Cytokinetics and Gilead Sciences.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.